OPKO Health, Inc. (NASDAQ:OPK) Shares Acquired by BNP Paribas Financial Markets

BNP Paribas Financial Markets increased its holdings in OPKO Health, Inc. (NASDAQ:OPKFree Report) by 349.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 271,872 shares of the biotechnology company’s stock after buying an additional 211,429 shares during the period. BNP Paribas Financial Markets’ holdings in OPKO Health were worth $411,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. River Wealth Advisors LLC acquired a new position in OPKO Health during the 3rd quarter valued at about $38,000. Northstar Group Inc. acquired a new position in OPKO Health during the 4th quarter valued at about $42,000. EP Wealth Advisors LLC boosted its stake in OPKO Health by 140.3% during the 3rd quarter. EP Wealth Advisors LLC now owns 30,900 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 18,041 shares during the period. Kestra Advisory Services LLC acquired a new position in OPKO Health during the 3rd quarter valued at about $79,000. Finally, Aigen Investment Management LP acquired a new position in OPKO Health during the 3rd quarter valued at about $86,000. 64.63% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Phillip Md Et Al Frost purchased 500,000 shares of the business’s stock in a transaction dated Thursday, March 14th. The shares were acquired at an average price of $0.89 per share, for a total transaction of $445,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 210,468,225 shares of the company’s stock, valued at $187,316,720.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have bought 1,863,997 shares of company stock worth $1,776,556 over the last 90 days. 47.26% of the stock is owned by company insiders.

OPKO Health Stock Up 3.6 %

NASDAQ OPK opened at $1.42 on Tuesday. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.91 and a quick ratio of 1.62. The company’s 50 day simple moving average is $1.28 and its 200 day simple moving average is $1.22. OPKO Health, Inc. has a 12 month low of $0.85 and a 12 month high of $2.24. The company has a market capitalization of $989.73 million, a P/E ratio of -4.06 and a beta of 1.76.

OPKO Health (NASDAQ:OPKGet Free Report) last released its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.03). OPKO Health had a negative return on equity of 17.89% and a negative net margin of 31.44%. The business had revenue of $173.70 million during the quarter, compared to the consensus estimate of $182.99 million. During the same quarter in the previous year, the firm earned ($0.02) earnings per share. The firm’s revenue for the quarter was down 26.9% compared to the same quarter last year. Equities research analysts expect that OPKO Health, Inc. will post -0.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

OPK has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of OPKO Health in a research note on Wednesday, May 8th. StockNews.com raised shares of OPKO Health to a “sell” rating in a research note on Tuesday. Piper Sandler reaffirmed an “overweight” rating and issued a $5.00 price target on shares of OPKO Health in a research note on Monday, April 1st. Finally, Barrington Research reaffirmed an “outperform” rating and issued a $1.50 price target on shares of OPKO Health in a research note on Monday, April 1st.

Read Our Latest Research Report on OPK

About OPKO Health

(Free Report)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.

Further Reading

Institutional Ownership by Quarter for OPKO Health (NASDAQ:OPK)

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.